Solara Active Pharma Sciences Limited — Board Meeting, 21-10-2024: Outcome of Board Meeting

Solara Active Pharma Sciences Limited reported its Q2 FY25 financial results, showing revenues of INR 3,472 million, despite a 5% decline QoQ. Gross margins improved significantly to 50.5%, up 600 bps QoQ due to a stronger focus on regulated markets, which contributed 76% to total revenues. EBITDA rose 46% QoQ to INR 616 million, with a robust EBITDA margin of 17.7%. The company aims for fiscal year revenue of around INR 15,000 million and an EBITDA range of INR 2,300 to 2,600 million.